Egetis Therapeutics AB (publ) financials
Egetis Therapeutics AB (publ)
549300RZCKGWRUBPMY22 | Line item | 2024 | 2023 |
|---|---|---|
| Income statement | ||
| Cost of sales | SEK 11.6M | SEK 11.0M |
| Gross profit | SEK 34.5M | SEK 46.6M |
| Other income | SEK 5.2M | SEK 8.9M |
| Administrative expenses | SEK 105.6M | SEK 86.2M |
| Operating profit (EBIT) | -SEK 329.4M | -SEK 324.8M |
| Net finance income / (cost) | -SEK 13.8M | -SEK 2.0M |
| Finance costs | SEK 25.9M | SEK 4.2M |
| Profit before tax | -SEK 343.2M | -SEK 326.8M |
| Income tax expense | SEK 300.0K | SEK 100.0K |
| Profit for the year | -SEK 343.6M | -SEK 326.9M |
| Total comprehensive income | -SEK 343.5M | -SEK 327.0M |
| Per share | ||
| Basic EPS | SEK -1.10 | SEK -1.30 |
| Diluted EPS | SEK -1.10 | SEK -1.30 |
| Free cash flow / share | SEK -0.73 | SEK -1.07 |
| Cash flow statement | ||
| Net cash from operating activities | -SEK 227.9M | -SEK 278.4M |
| Net cash from investing activities | -SEK 1.2M | SEK 0 |
| Purchase of PP&E (capex) | SEK 0 | SEK 0 |
| Net cash from financing activities | SEK 270.9M | SEK 458.9M |
| Proceeds from borrowings | SEK 0 | SEK 108.8M |
| Repayments of borrowings | SEK 7.7M | SEK 3.0M |
| Lease liability payments | SEK 2.5M | SEK 2.6M |
| Net change in cash | SEK 41.8M | SEK 180.4M |
| Balance sheet | ||
| Total assets | SEK 792.3M | SEK 760.2M |
| Non-current assets | SEK 412.2M | SEK 414.3M |
| Right-of-use assets | SEK 2.6M | SEK 4.3M |
| Current assets | SEK 380.1M | SEK 345.9M |
| Inventories | SEK 1.0M | SEK 700.0K |
| Trade & other receivables | SEK 15.5M | SEK 28.2M |
| Cash & equivalents | SEK 351.0M | SEK 303.3M |
| Total equity | SEK 492.9M | SEK 545.6M |
| Non-current liabilities | SEK 95.2M | SEK 110.8M |
| Long-term borrowings | SEK 84.1M | SEK 103.4M |
| Current liabilities | SEK 204.2M | SEK 103.9M |
| Deferred tax liabilities | SEK 500.0K | SEK 0 |
| Derived metrics | ||
| Free cash flow | -SEK 227.9M | -SEK 278.4M |
| Operating margin | -714.5% | -563.9% |
| Net margin | -745.3% | -567.5% |
| Return on equity | -69.7% | -59.9% |
| Cash conversion ratio | 0.66× | 0.85× |
| Other reported items | ||
| Accruals and Deferred Income Including Contract Liabilities | SEK 137.2M | SEK 63.0M |
| Additional Paidin Capital | SEK 2.06B | SEK 1.78B |
| Adjusted Weighted Average Shares | 310.9M | 260.0M |
| Adjustments For Increase Decrease In Trade and Other Payables | SEK 75.2M | SEK 53.8M |
| Adjustments For Reconcile Profit Loss | SEK 88.6M | SEK 30.9M |
| Cash Flows From Used In Decrease Increase In Restricted Cash and Cash Equivalents | SEK 0 | SEK 0 |
| Cash Flows From Used In Operations Before Changes In Working Capital | -SEK 316.6M | -SEK 309.3M |
| Cash Flows Used In Obtaining Control of Subsidiaries Or Other Businesses Classified As Investing Activities | SEK 1.2M | SEK 0 |
| Current Borrowings and Current Portion of Noncurrent Borrowings | SEK 30.1M | SEK 5.2M |
| Current Prepayments and Current Accrued Income Other Than Current Contract Assets | SEK 4.5M | SEK 5.5M |
| Current Tax Liabilities Current | SEK 200.0K | SEK 100.0K |
| Deferred Tax Assets | SEK 600.0K | SEK 0 |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | SEK 5.8M | -SEK 4.8M |
| Equity and Liabilities | SEK 792.3M | SEK 760.2M |
| Finance Income | SEK 16.5M | SEK 4.9M |
| Gains Losses On Change In Fair Value of Derivatives | -SEK 4.5M | -SEK 2.7M |
| Income Taxes Paid Refund Classified As Operating Activities | SEK 300.0K | SEK 100.0K |
| Increase Decrease Through Sharebased Payment Transactions | SEK 6.2M | SEK 7.2M |
| Interest Paid Classified As Operating Activities | SEK 8.5M | SEK 4.1M |
| Interest Received Classified As Operating Activities | SEK 6.9M | SEK 4.9M |
| Issue of Equity | SEK 301.5M | SEK 381.9M |
| Issued Capital | SEK 20.4M | SEK 15.4M |
| Licences and Franchises | SEK 3.2M | SEK 4.3M |
| Miscellaneous Other Operating Expense | SEK 7.6M | SEK 13.4M |
| Noncurrent Payables On Social Security and Taxes Other Than Income Tax | SEK 10.2M | SEK 5.1M |
| Number of Shares Outstanding | 359.2M | 292.6M |
| Other Adjustments For Noncash Items | SEK 27.0M | SEK 17.7M |
| Other Comprehensive Income | SEK 100.0K | -SEK 100.0K |
| Other Current Liabilities | SEK 11.0M | SEK 6.8M |
| Other Current Receivables | SEK 8.1M | SEK 8.2M |
| Other Noncurrent Financial Assets | SEK 800.0K | SEK 800.0K |
| Other Noncurrent Liabilities | SEK 400.0K | SEK 2.2M |
| Other Reserves | SEK 24.8M | SEK 16.7M |
| Payments For Share Issue Costs | SEK 18.8M | SEK 26.3M |
| Proceeds From Issuing Shares | SEK 301.5M | SEK 381.9M |
| Proceeds From Sale Or Issue of Treasury Shares | -SEK 1.5M | SEK 0 |
| Purchase of Treasury Shares | SEK 1.5M | — |
| Research and Development Expense | SEK 146.2M | SEK 194.0M |
| Retained Earnings | -SEK 1.61B | -SEK 1.27B |
| Revenue From Contracts With Customers | SEK 46.1M | SEK 57.6M |
| Sales and Marketing Expense | SEK 109.7M | SEK 86.6M |
| Share Issue Related Cost | SEK 18.8M | SEK 26.3M |
| Trade and Other Current Payables To Trade Suppliers | SEK 25.7M | SEK 28.7M |
| Weighted Average Shares | 306.5M | 256.8M |
Every line item above is a fact tagged in Egetis Therapeutics AB (publ)'s annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (SEK), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.